FGF-23 epitope peptides and methods of use thereof
US-10744184-B2 · Aug 18, 2020 · US
US11358996B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11358996-B2 |
| Application number | US-201916711821-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2019 |
| Priority date | Aug 12, 2016 |
| Publication date | Jun 14, 2022 |
| Grant date | Jun 14, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
Opening claim text (preview).
The invention claimed is: 1. A method of improving resistance to egg shell breakage and/or improving egg shell strength, comprising administering to a laying hen greater than 37 weeks in age an effective amount of an FGF-23 epitope peptide to improve resistance to egg shell breakage and/or improve the egg shell strength of eggs laid by the hen, wherein the FGF-23 epitope peptide comprises SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:9, and wherein the FGF-23 epitope peptide is conjugated to a carrier protein. 2. The method of claim 1 , further comprising administering to the laying hen a booster administration one or more weeks or more after the first administration, wherein the booster administration comprises an effective amount of an FGF-23 epitope peptide to improve resistance to egg shell breakage and/or improve the egg shell strength of eggs laid by the hen, wherein the FGF-23 epitope peptide comprises SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:9, and wherein the FGF-23 epitope peptide is conjugated to a carrier protein. 3. The method of claim 2 , wherein the carrier protein is bovine gamma globulin, bovine serum albumin, keyhole limpet hemocyanin, or ovalbumin. 4. The method of claim 1 , wherein the laying hen is a chicken, a turkey, a duck, a goose, a peafowl, an emu, a pheasant, a guinea fowl, or a quail. 5. The method of claim 1 , wherein administering is oral, aerosol, or parenteral administration. 6. The method of claim 1 , wherein improved resistance to egg shell breakage and/or improved egg shell strength is determine by one or more of: load resistance testing with a 50-kg load cell, 2 mm/s test speed, 0.001 kg trigger force, and a 50 mm diameter cylindrical probe; egg specific gravity measured by flotation in sodium chloride and water solutions having sodium chloride concentrations of 1.070, 1.074, 1.078, 1.082, 1.086, 1.090, 1.094, and 1.098M; and shell weight.
Vertebrate antigens (from snakes A61K39/38) · CPC title
Fibroblast growth factor [FGF] · CPC title
characterised by the link between antigen and carrier · CPC title
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title
against growth factors {; against growth regulators} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.